17:58 , Jan 11, 2019 |  BC Week In Review  |  Clinical News

Plinabulin meets in Phase III for chemotherapy-induced neutropenia

BeyondSpring Inc. (NASDAQ:BYSI) reported interim data on Dec. 6 showing that plinabulin (BPI-2358) met the primary endpoint in the Phase III portion of the Phase II/III Protective-1 trial to treat chemotherapy-induced neutropenia in patients with...
20:58 , Mar 1, 2018 |  BC Innovations  |  Translation in Brief

New Therapeutic Targets and Biomarkers: February 2018

New Therapeutic Targets and Biomarkers: February 2018 Select top therapeutic targets and biomarkers covered by BioCentury or added to the BCIQ database during February 2018. Therapeutic targets are defined as any protein, gene or other...
13:10 , Feb 16, 2018 |  BC Week In Review  |  Clinical News

BeyondSpring reports Phase II data for plinabulin to prevent chemotherapy-induced neutropenia

BeyondSpring Inc. (NASDAQ:BYSI) reported top-line data from 55 patients with advanced or metastatic non-small cell lung cancer (NSCLC) who failed platinum-based therapy in the Phase II portion of the Phase II/III Study 105 (Protective-1) to...